From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences’ antibody-oligonucleotide conjugate technology, to Nurix and Seagen collaborating on a targeted protein degradation conjugate, there is now a staggering amount of investment and collaboration in the novel conjugates space.

As highlighted above, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma, Dyne Therapeuitcs and Alnylam are now awaiting clinical validation, and others continue to innovate in conjugate design, it is an exciting time for the next-generation conjugates field.

Covering case-study led presentations on novel design concepts, key translational and clinical development challenges, and addressing challenging CMC roadblocks, the Next-Generation Conjugates Summit is your only event uniting developers of a wide array of novel formats and payloads, with conjugate modality types including antibody-oligonucleotide conjugates, fragment-drug conjugates, Targeted Radiopharmaceutical Conjugates, small molecule-drug conjugates, bispecific-drug conjugates and more!

This is the only event to unite 100+ drug developers from companies of different modality types that would not normally come together, so make sure to join likeminded conjugate developers to learn, collaborate and innovate and expand on the potential of conjugate drugs.

Learn more here: https://ter.li/q5wf9x